Functional screens on single-cell transcriptomes of genotypically-defined minimal residual disease cells to unravel specific vulnerabilities of treatment resistant multiple myeloma (FUTURE)

Basic Information

Funding Cycle : 2023-2024
Name : Niccolo Bolli
Type of Award : Translational Research Award
Home Institution : Fundació Clínic per a la Recerca Biomèdica


The research proposed in this grant stems from
the hypothesis that phenotypic hierarchies between distinct clonal cells may explain MM ontogeny
and relapse patterns, and that through innovative approaches this can be harnessed to provide better
biomarkers of treatment response and vulnerabilities to eradicate residual cells. I propose an unbiased
simultaneous analysis of B-cell receptor (BCR) sequence and whole-transcriptome from single cells, using
innovative approaches to deconvolute heterogeneity and opening a new frontier of functional analysis of
genetic and phenotypic determinants of disease evolution from diagnosis to minimal residual disease (MRD).

Why Become a Member

The International Myeloma Society is a professional, scientific, and medical society established to bring together clinical and experimental scientists involved in the study of myeloma. The purpose of this society is to promote research, education, clinical studies (including diagnosis and treatment), workshops, conferences, and symposia on all aspects of multiple myeloma worldwide.

The IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners.

Stay updated on our Events